Clin2
NCT06613854Possibly a fitRecruiting

Early combination therapy for type 2 diabetes

Type 2 Diabetes Mellitus (T2DM)

Treatments studied

Part of Hormones & metabolism clinical trials.

This study tests if starting two newer diabetes drugs (empagliflozin and semaglutide) soon after diagnosis, along with metformin, helps control blood sugar better than metformin alone. It's for people diagnosed with type 2 diabetes in the last two years who are already taking a high dose of metformin.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
90 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • Diagnosed with type 2 diabetes within the past 2 years
  • Age between 18 and 70 years old
  • Currently taking metformin at a daily dose of at least 1500 mg
  • HbA1c (average blood sugar) 8.0% or lower
  • No past use of SGLT2i, GLP-1RA, or DPP-4 inhibitor drugs (like empagliflozin, semaglutide, or sitagliptin)
  • Body mass index (BMI) between 22 and 40

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07272343Recruiting· Phase 4
Semaglutide vs. diet changes for new type 2 diabetes

This study compares a weekly injection called semaglutide with a calorie-restricted diet to see which helps control blood sugar better. If you have just been diagnosed with type 2 diabetes and have overweight, this trial might help you choose a treatment path.

Jiangxi, Nanchang
NCT07628985Not yet recruiting· Phase 3
Testing Bofanglutide for Type 2 Diabetes Control

This study tests a new medication called bofanglutide in adults with type 2 diabetes who are currently taking metformin. The medication works similarly to a hormone that helps control blood sugar, and the study aims to see if it can help lower blood sugar levels and manage weight better.

Mexico City, Cuauhtémoc
NCT06894784Recruiting· Phase 3
Combining two diabetes drugs with an automated insulin pump

This trial tests if adding semaglutide and empagliflozin to your automated insulin delivery system (like a smart pump) can improve blood sugar control for adults with type 1 diabetes. It may help with both glucose levels and weight management.

Montreal, Quebec
NCT06762314Recruiting· Phase 2
Empagliflozin or semaglutide for overweight people with type 1 diabetes

This study tests two different medicines (empagliflozin or semaglutide) added to your usual insulin to see if they help with blood sugar control and weight loss in people with type 1 diabetes who are overweight or have obesity. It may be a good fit if your diabetes is not well controlled with insulin injections alone.

Tanta
NCT06959784Enrolling by invitation· Phase 4
A study on new diabetes drugs for heart health and remission

This trial tests if newer diabetes medications can reduce heart risk and help achieve diabetes remission in people newly diagnosed with type 2 diabetes. It may be an option if you have not taken diabetes drugs before or stopped them over three months ago, and your blood sugar and weight are in certain ranges.

Beijing
NCT07046273Not yet recruiting· Phase 3
Semaglutide for type 2 diabetes: a phase 3 trial

This trial tests if a new form of semaglutide works as well as the approved drug Ozempic for lowering blood sugar. It's for adults with type 2 diabetes who are already taking metformin and need better sugar control.

Hear when a new Type 2 Diabetes Mellitus (T2DM) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.